1. [Role of neuroendocrine cells in prostate cancer progression].
- Author
-
Sciarra A, Innocenzi M, Ravaziol M, Minisola F, Alfarone A, Cattarino S, Panebianco V, Buonocore V, Gentile V, and Di Silverio F
- Subjects
- APUD Cells metabolism, Adenocarcinoma drug therapy, Adenocarcinoma pathology, Adult, Antineoplastic Agents, Hormonal therapeutic use, Calcitonin metabolism, Cell Transformation, Neoplastic drug effects, Chorionic Gonadotropin metabolism, Chromogranin B metabolism, Chromogranins metabolism, Diagnosis, Differential, Disease Progression, Humans, Male, Middle Aged, Neoplasm Invasiveness, Neuroendocrine Cells drug effects, Neuroendocrine Tumors drug therapy, Neuroendocrine Tumors pathology, Nuclear Proteins metabolism, Parathyroid Hormone-Related Protein metabolism, Peptide Fragments metabolism, Peptide Hormones metabolism, Prostatic Neoplasms drug therapy, Prostatic Neoplasms pathology, Serotonin metabolism, Transcription Factors metabolism, Treatment Failure, Adenocarcinoma metabolism, Biomarkers, Tumor metabolism, Chromogranin A metabolism, Neuroendocrine Cells metabolism, Neuroendocrine Tumors metabolism, Prostatic Neoplasms metabolism
- Abstract
Neuroendocrine (NE) cells represent the third epithelial cell type on normal prostatic tissue (in addition to basal and secretory cells). They are localized in all regions of the human prostate at birth but rapidly decrease in the peripheral prostate after birth, and then reappear at puberty. After puberty, their number seems to increase until an apparently optimum level is reached, which persists between the age of 25 and 54. NE cells were defined by Pearse as APUD to refer to chemical characteristics of amine precursor uptake and decarboxylation, common to the cells of this system. The most predominant product of prostatic NE cells is Chromogranin A, but they also produce serotonin, CgB, secretogranin or CgC, thyroid-stimulating hormone-like peptide, calcitonin, katacalcin, PTHrP and a-human chorionic gonadotropin-like peptide. NE cells in normal and neoplastic prostates are devoid of androgen receptors, but they express epidermal growth factor (EGF) receptor and c-erbB-2. For these reason NE cells are androgen-insensitive. The NE component of prostate adenocarcinoma is resistant to hormone therapy; some studies showed that the number of NE tumor cells and CgA serum levels increase with the recovery of human prostate tumor from hormonal therapy. Currently there are no clinical data available to support an active role of radiotherapy in NE differentiation.
- Published
- 2011
- Full Text
- View/download PDF